You are here

Imbruvica

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Fierce Pharma

Flag link:

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

Fierce Pharma

Flag link:

AbbVie removes two approvals for blood cancer drug Imbruvica

AbbVie removes two approvals for blood cancer drug Imbruvica

BioPharma Dive

Flag link:

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Endpoints

Flag link:

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

Fierce Pharma

Flag link:

AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease

AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease

Fierce Pharma

graft vs host disease

Flag link:

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

BioSpace

clinical trials

Flag link:

ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?

ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?

Fierce Pharma

Flag link:

AbbVie files sNDA to FDA for chronic graft versus host disease therapy

AbbVie files sNDA to FDA for chronic graft versus host disease therapy

Pharmaceutical Business Review

graft vs host disease

Flag link:

ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again

ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again

Fierce Biotech

clinical trials

Flag link:

Court upholds AbbVie's patents on blockbuster cancer drug Imbruvica, generics unlikely until 2032

Court upholds AbbVie's patents on blockbuster cancer drug Imbruvica, generics unlikely until 2032

Endpoints

Flag link:

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

Endpoints

clinical trials

Flag link:

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

Motley Fool

Flag link:

AZ says Calquence is a safer drug than Imbruvica

AZ says Calquence is a safer drug than Imbruvica

Pharmaforum

Flag link:

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

Fierce Pharma

Flag link:

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Pharmaceutical Business Review

Flag link:

AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman

AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman

Fierce Pharma

Flag link:

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

Fierce Pharma

Flag link:

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

Endpoints

Flag link:

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Pharmaceutical Business Review

Flag link:

Pages